ReviewMedical hypothesis, discovery & innovation ophthalmology journal2013
Glaucomatous optic neuropathy management: the role of neuroprotective agents.
Review in Medical hypothesis, discovery & innovation ophthalmology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Review
- Betalain exerts a protective effect against glaucoma is majorly through the association of inflammatory cytokines.AMB Express · 2020Article
- Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.Scientific reports · 2019Article
- Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost.Investigative ophthalmology & visual science · 2017Article
- Afraid of the Dark; Raising Awareness of Societies Each Year during World Glaucoma Week.Iranian journal of public health · 2015Article
- Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model.Investigative ophthalmology & visual science · 2014Article
- The Role of Magnesium in the Pathogenesis and Treatment of Glaucoma.International scholarly research notices · 2014Review
- VISION 2020: The Right to Sight in 7 Years?Medical hypothesis, discovery & innovation ophthalmology journal · 2013Article
- Artificial intelligence in ophthalmology.Romanian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a major cause of worldwide irreversible blindness. The central role of raised intraocular pressure (IOP) is being questioned as many patients continue to demonstrate a clinically downhill course despite initial control of IOP. The latest concept of recognizing glaucoma as a multifactorial, progressive, neurodegenerative disease of retinal ganglion cells (RGCSs) associated with characteristic axon degeneration in the optic nerve emphasizes that several pressure-independent mechanisms are responsible for the development and progression of glaucomatous optic neuropathy. Neuroprotection as a pharmacological strategy to mitigate retinal ganglion cell death has been a popular current approach. The aim of this review is to evaluate the neuroprotective potential of calcium channel blockers in glaucomatous optic neuropathy.
Indexed as
Identifiers
24600641PMC3939751W2104675672What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.